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ABSTRACT
The discovery of EGFR mutations and EML4-ALK gene rearrangements has 
radically changed the therapeutic scenario for patients with advanced non-small cell 
lung cancer. ALK and EGFR tyrosine-kinase inhibitors showed better activity and 
efficacy than standard chemotherapy in the first and second line treatment settings, 
leading to a clear advantage in overall survival of advanced non-small cell lung cancer 
patients harboring these genetic alterations.
Historically the coexistence of EGFR mutations and EML4-ALK rearrangements 
in the same tumor has been described as virtually impossible. Nevertheless many 
recent observations seem to show that it is not true in all cases.
In this review we will discuss the available literature data regarding this 
rare group of patients in order to give some suggestions useful for their clinical 
management. Furthermore we report here two cases of concomitant presence of both 
alterations that will help us in the development of discussion.
INTRODUCTION
Lung tumors are very common, both in men and 
women. They represent the leading cause of cancer death 
in males and the third most common cause in women. 
Although the 5-years survival rate has moderately increased 
in the last years (from 8% to 13%) lung cancer remains 
associated with a very poor prognosis. [1] The disease is 
frequently metastatic at diagnosis and therefore treatments 
are rarely curative. However recently, few but significant 
steps forward have been made in the treatment of advanced 
stage non-small cell lung cancer (NSCLC). [2, 3]
In recent years research has focused on molecular 
characteristics of lung cancer, highlighting the role of 
specific genes involved in tumor growth. These genes 
have been shown to be important therapeutic targets, 
especially in advanced adenocarcinomas. [4] In particular 
activating EGFR mutations were identified in 10-15% of 
Caucasian and in 40% of Asian patients. Their presence is 
the most important predictor of good response to EGFR-
tyrosine-kinase inhibitors (TKIs) therapy. In patients with 
advanced EGFR mutated NSCLC many trials compared 
chemotherapy and EGFR-TKIs in first line setting and 
showed the clear superiority of the latter. [5] Furthermore 
after the progression to first and second generation EGFR-
TKIs (gefitinib, erlotinib and afatinib), the third-generation 
drugs, have showed very high activity, especially in 
patients harboring EGFR T790M mutation, that is the 
main cause of resistance to first line TKI therapy. [6, 7]
The rearrangement of ALK with EML4 oncogene 
on the chromosome 2 short arm is another important 
therapeutic target. Such aberration activates a specific 
tyrosine kinase, involved in the processes of survival and 
cell proliferation and it is found in about 3-7% of lung 
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 35), pp: 59889-59900
                                                                        Review
Oncotarget59890www.impactjournals.com/oncotarget
adenocarcinomas in Caucasian patients. The determination 
of EML4-ALK gene rearrangement is necessary to select 
patients to be treated with specific ALK-TKIs. These drugs 
have shown to be more active than chemotherapy in all 
the lines of treatment in which they have been testes, even 
in patients progressing after one or two different ALK-
TKIs. [8] These outstanding results underline the need of a 
thorough molecular characterization of advanced NSCLC, 
especially in never smokers with non squamous histology. 
Historically, the coexistence of EGFR mutations and EML4-
ALK rearrangements have been described as extremely rare, 
perhaps because of its low prevalence and the sensitivity of 
diagnostic tools. In contrast recently published case reports 
and case series suggest that this is not true for all patients 
[9–11]. In this paper we performed an accurate literature 
review and we reported two new cases of patients diagnosed 
with lung adenocarcinoma, exhibiting both EGFR mutation 
and EML4-ALK rearrangement. Finally we did a qualitative 
synthesis of results of the review.
RESULTS
Case presentation
Case 1
Patient One was a 52-year-old never smoker Caucasian 
male, diagnosed with stage IV lung adenocarcinoma in 
May 2012. A CT scan showed lung and bone metastasis at 
diagnosis. A biopsy of the lung mass revealed the presence 
of EGFR exon 19 deletion and therapy with gefitinib was 
initiated. In August 2012, after 2 months of gefitinib (250 
mg daily), the drug was stopped for liver and skin toxicity. 
The patient then received two cycles of chemotherapy with 
cisplatin and gemcitabine and reported progressive disease 
(PD) as best response. Considering the previous evidence of 
EGFR exon 19 deletion and the discontinuation of gefitinib 
due to toxicity, we decided to start treatment with erlotinib 
(150mg daily). Nevertheless lung and bone PD was evident 
after 4 months. So the patient was treated with pemetrexed 
and obtained partial response (PR) after 4 cycles and PD 
on mediastinal nodes after 8 cycles. In December 2013 
palliative radiotherapy (RT) (total 30 Gy) on mediastinum 
and pulmonary hilum was performed. After a new pleural 
PD the assessment of EML4-ALK rearrangement on the 
original biopsy demonstrated the presence of EML4-ALK 
fusion gene. Crizotinib (500mg daily) was administered 
from February 2014 until October 2015 when a brain MRI 
showed the presence of brain metastases. So the patient 
underwent whole brain radiotherapy (WBRT) and started 
chemotherapy with vinorelbine. After 3 cycles, complicated 
by gastrointestinal toxicity, a CT scan showed lung PD and 
the drug was stopped. In April 2016 the ECOG performance 
status (PS) of the patient was 2 and he started treatment with 
ceritinib (750 mg daily) in the context of a clinical trial. 
Unfortunately, the disease progressed rapidly and the patient 
died in July 2016.
Case 2
Patient Two, a 43-year-old never smoker Caucasian 
woman, underwent a right lower lobectomy with 
systematic nodal dissection in April 2012. The initial 
pathologic diagnosis was lung adenocarcinoma stage IIIa 
(pT3 pN1 Mx), KRAS wild-type, harboring EGFR exon 
19 deletion and EML4-ALK rearrangement. We decided 
to start adjuvant chemotherapy but in June 2012, before 
the start of treatment, a brain MRI showed multiple brain 
metastases and a CT scan demonstrated the presence of 
lung and nodal disease. So the patient underwent WBRT 
and started therapy with gefitinib (250 mg daily) which 
continued until March 2014. She obtained a PR as best 
response. In March 2014 a new brain MRI demonstrated 
a slight cerebral PD and the patient was switched to 
crizotinib (500 mg daily), that was stopped after 4 days 
because of a G4 gastrointestinal toxicity. Due to the 
patient’s refusal of chemotherapy, she started erlotinib 
(150 mg daily). She continued therapy until January 
2016, obtaining a stabilization of thoracic disease and a 
slow asymptomatic progression of cerebral disease. In 
January 2016 the brain MRI showed a significant cerebral 
PD and a CT scan evidenced lung and pleural PD. The 
patient was still in good clinical condition (ECOG PS = 
0) thus she was enrolled in a clinical trial and received 
ceritinib (750 mg daily). After 2 cycles a chest/abdomen 
CT scan and brain MRI showed PR in both lung and brain. 
At present the patient keeps a good PS and continues 
ceritinib. The dose was reduced to 450 mg daily due to G2 
gastrointestinal toxicity. The disease is stable.
Descriptive analysis and qualitative synthesis
We identified 98 cases of concomitant EGFR 
mutation and ALK rearrangement in NSCLC patients 
from a literature search. In this paper we will describe a 
total of 100 cases, including our 2 patients (Table 1). The 
main patient characteristics are consistent with previous 
findings about patients with the sole EGFR mutation or 
EML4-ALK translocation [52]. There is a prevalence of 
women (51 female, 31 male, 18 not reported), Asian (53 
Asian, 30 Caucasian, 17 not reported) and never smoker 
patients (58 never smokers, 15 smokers, 27 not reported). 
We are here considering all patients treated with at least 
one TKI (EGFR or ALK-TKIs) and since some patients 
had more than one treatment with the same class of TKI 
we are analyzing together all treatments administered for 
each class (lines of therapy). Fifty one patients received 
at least one EGFR-TKI, with a total of 56 EGFR-TKI 
lines administered. Considering only the 53 EGFR-TKI 
lines evaluable for response, independently from the 
setting, disease control (CR or PR or SD) was achieved 
in 37 cases (69.8%) with 23 objective responses reported 
(43.4%). Thirty-seven patients were treated with at least 
one ALK-TKI (39 evaluable lines of treatment). In these 
patients disease control was achieved in 31 cases (79.5%) 
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Table 1: Clinical and biological characteristics of patients with both EML4-ALK rearrangement and EGFR mutation
Author Pts characteristics Biomolecular characterization
EGFR-TKI 
treatment ALK-TKI treatment Other treatments
Zhao N 
et al [9]
1 pts. F,48 Y, NS, 
Asiatic
-EGFR exon 21 (L861Q) 
mutation
-EML4-ALK variant NR
-first line 
erlotinib. BR: 
SD (PFS 5,3 
mts)
-third line crizotinib. BR 
:SD (PFS 3,5 mts)
-fourth line brigatinib. 
BR:PR
-second line nedaplatin 
+ pemetrexed. BR: PD 
(3 cycles)
-fifth line axitinib. BR: 
PD
Sweis RF 
et al [10]
4 pts. 2M 2F, 
median age 53 Y, 2 
CS 2 NS, Asiatic
-EGFR: 1 pts exon 19 
deletion, 1pts exon 21 
(L861Q) mutation, 1pts exon 
21 (L858R) mutation, 1 pts 
exon 23 polymorphism
-EML4-ALK variant NR
-pts N 1 
Manteinance 
therapy erlotinib 
+ bevacizumab. 
BR: PR (PFS 12 
mts)
-pts N 3 first line 
erlotinib. BR: 
PD (PFS 2 mts)
-pts N 4 third 
line erlotinib. 
BR : PD (PFS 2 
mts)
-pts N 1 third line 
crizotinib. BR : SD (PFS 
9 mts)
-pts N2 third line 
crizotinib. BR : PD (PFS 
1 mts)
-pts N 3 second line 
crizotinib. BR : PD (PFS 
1 mts)
-pts N 4 first line 
crizotinib. BR:PD
-pts N 1 first 
line carboplatin 
+ paclitaxel + 
bevacizumab. BR: PR 
(6 cycles)
-pts N 1 second line: 
pemetrexed. BR: PD 
(PFS 3 mts)
-pts N2 first line 
carboplatin + 
pemetrexed. BR: PR (6 
cycles)
-pts N2 second-line 
docetaxel. BR: PD
-pts N 4 second-
line carboplatin + 
pemetrexed. BR: PR (4 
cycles)
Xu CW 
et al [11]
1 pts. F, 71 Y, NS, 
Asiatic
-EGFR exon 19 deletion
-EML4-ALK variant 1
-first line 
gefitinib. BR: 
PR
NT NT
Zhang X 
et al [20]
1 pts. F, NS, Asiatic -EGFR exon 19 deletion
-EML4-ALK variant 3 b
NR NT NR
Koivunen 
JP et al [21]
1 pts. NR clinical 
data
-EGFR exon 19 deletion
-EML4-ALK variant NR
NT NT NT
Kuo YW 
[22]
1 pts. F,72 Y, NS, 
Asiatic
-EGFR exon 19 deletion
-EML4-ALK variant 1
-first line 
gefitinib. BR : 
PR (PFS 7 mts)
NT NR
Sasaki T 
et al [23]
3 pts. NR clinical 
data
-EGFR: 1 pts exon 19 
deletion,1pts exon 21 
(L858R) mutation, 1 
pts mutation A767_
V769dupASV
-EML4-ALK variant NR
-2 pts treated 
with erlotinib. 
BR : 2 pts PR (9 
mts, 5 mts PFS 
respectively)
NT NR
Tiseo M 
et al [24]
1 pts. M,48 Y, NS, 
Caucasian
-EGFR exon 19 deletion
-EML4-ALK variant 1
-second line 
erlotinib. BR : 
PD (PFS 2 mts)
NT -first line cisplatin + 
gemcitabine. BR: PR 
(4 cycles).
Popat S 
et al [25]
1 pts. F, 65 Y, NS , 
Caucasian
-EGFR exon 19 deletion
-EML4-ALK variant NR
-first line 
erlotinib. BR : 
CR (PFS 25 mts)
NT -adjuvant carboplatin + 
vinorelbine (4 cycles)
Tanaka H 
et al [27]
1 pts. M, 39 Y, LS, 
Asiatic
-EGFR exon 21 (L858R) 
mutation
-EML4-ALK variant 3B
-third line 
erlotinib. BR : 
PD (PFS 1 mts)
NT -first line cisplatin + 
docetaxel. BR: PD 
(3 cycles)
-second line 
pemetrexed. BR:PR 
(15 cycles)
-fourth line NR 
chemotherapy. BR: PD
(Continued )
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Author Pts characteristics Biomolecular characterization
EGFR-TKI 
treatment ALK-TKI treatment Other treatments
Lee JK 
et al [28]
4pts. 1 pts M,73 Y, 
LS, Asiatic. 3 pts 
NR clinical data
-EGFR 2 pts exon 19 
deletion, 1pts exon 21 
(L858R) mutation,1 pts exon 
21 (L718P) mutation
-EML4-ALK variant NR
-1 pts first line 
gefitinib. BR : 
PD (PFS 1 mts)
-1 pts second line 
crizotinib. BR : PR (PFS 
9 mts)
NT
Pilotto et al 
[29]
1 pts. F,78Y, NS, 
Caucasian
-EGFR exon 21 (L861Q) 
mutation
-EML4-ALK increased GCG
-first line 
gefitinib. BR : 
PD (PFS 2 mts)
-second line crizotinib. 
BR : SD (PFS 4 mts)
NT
Miyanaga 
et al [30]
1 pts. F, 55 Y, NS, 
Asiatic
-EGFR exon 19 deletion
-EML4-ALK variant 2
-second line 
gefitinib. BR:PD 
(PFS 2 mts)
-third line 
erlotinib. BR : 
PD (PFS 3 mts)
-fifth line NR ALK TKI. 
BR: SD (PFS 4 mts)
-first line cisplatin + 
pemetrexed. BR: SD 
(4 cycles)
-fourth line docetaxel. 
BR: PD (2 cycles)
Chen X 
et al [31]
1 pts. M,56 Y, HS, 
Asiatic
-EGFR exon 19 deletion
-EML4-ALK variant NR
-second line 
erlotinib. BR:SD
-third line crizotinib. 
BR:CR
-first line cisplatin 
+ gemcitabine (1 
cycle interrupted for 
toxicity)
Santelmo C 
et al [32]
1 pts. F,52 Y, HS, 
Caucasian
-EGFR exon 19 deletion
-EML4-ALK variant NR
-neoadjuvant 
gefitinib. BR:PR
NT NT
Chiari R 
et al [33]
1 pts. F,67 Y, NS 
Caucasian
-EGFR exon 21 (L858R) 
mutation
-EML4-ALK variant NR
-third line 
erlotinib/
afatinib. BR:SD
-sixth line crizotinib. 
BR:PR
-first line cisplatin + 
gemcitabine. BR: SD 
(6 cycles)
-second line 
carboplatin + 
pemetrexed. BR: SD 
(8 cycles)
-fourth line docetaxel. 
BR: SD (10 cycles)
-fifth line pemetrexed. 
BR: SD (6 cycles)
Yang JJ 
et al [34]
13 pts. 8 F 5 M, 
12 NS 1 LS, 59 Y 
(median), Asiatic
-EGFR: 7 pts exon 19 
deletion, 4 pts exon 21 
(L858R) mutation, 1pts exon 
20 mutation, 1pts K757 R 
mutation
-EML4-ALK variant: 5 pts 
V1, 2 pts V3a/V3b, 1 pts 
V4b, 1 pts V5, 1 pts V6b, 3 
pts NA
-10 pts receiving 
first-line EGFR-
TKI. BR: 8 PR 
(4 pts, 3 pts, 
and 1pts treated 
with erlotinib, 
gefitinib, 
and afatinib 
respectively), 1 
SD (afatinib); 
and 1 PD 
(erlotinib). ORR: 
80% (8/10 pts). 
Median PFS: 
11.2 mts
-1 pts received first line 
crizotinib. BR:PR (PFS 
15 mts) (NR previous 
EGFR TKI treatment)
-3 pts received second 
line crizotinib. BR: 1 
pts PR, 1 pts PD, 1 pts 
SD (all pts previously 
treated with EGFR TKI. 
BR: 1 pts PD, 1 pts PR, 
1 pts PR)
NR
Baldi et al 
[35]
1 pts. M, 68 Y, NS, 
Caucasian
-EGFR exon 21 (L858R) 
mutation
-EML4-ALK variant NR
-second line 
erlotinib .BR:SD 
(PFS 3 years)
-third line crizotinib. BR 
: PR
-first-line cisplatin 
+ pemetrexed. After 
4 cycles BR:SD. 
Maintenance 
pemetrexed/ placebo. 
BR:SD (15 cycles)
Jurgens 
et al [36]
1 pts. M, 69 Y, LS, 
Caucasian
-EGFR exon 21 (861) 
mutation
-EML4-ALK variant NR
-first line 
gefitinib. BR:PD
NT -second line 
carboplatin + 
pemetrexed + 
bevacizumab. BR: PR
(Continued )
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Author Pts characteristics Biomolecular characterization
EGFR-TKI 
treatment ALK-TKI treatment Other treatments
Cabillic F 
et al [37]
8 pts. 5 M 3 F, 
median age 65 
Y, Smoke NR, 
Caucasian
-EGFR: 3 pts exon 19 
deletion, 4 pts exon 21 
(L858R) mutation, 1 pts 
L858R + T790 M exon 21 
mutation
-EML4-ALK variant NR
-2 pts first line 
gefitinib. BR:NR
-1 pts second line 
crizotinib. BR : PR (NR 
previous EGFR-TKI 
treatment)
NR
Wang J 
et al [38]
1 pts. Asiatic. Other 
clinical data NR
-EGFR exon21 (L858R) 
mutation
-EML4-ALK variant NR
NR NR NR
Kim TJ 
et al [39]
5 pts. 3 M 2 F, 
median age 62 Y, 4 
NS 1 HS, Asiatic
-EGFR: 3 pts exon 19 
deletion, 2 pts exon 21 
(L858R) mutation
-EML4-ALK variant NR
NR NR NR
Won JK 
et al [40]
14 pts (1 pts 
previously reported 
by Lee JK et al). 6 
M 8 F, median age 
55 Y, 12 NS 2 LS, 
Asiatic
-EGFR: 9 pts exon 19 
deletion, 2 pts exon 19 
L747P, 1 pts exon 21 L861Q, 
1 pts exon 21 L858R, 1 pts 
exon 21 E868K
-EML4-ALK variant NR
-3 pts treated 
with gefitinib. 
BR: 2 pts PD, 1 
pts SD (PFS 6 
mts)
-6 pts treated with 
crizotinib. BR : 5 pts 
PR 1 pts SD (only 1 pts 
previously treated with 
gefitinib PD→PR)
-2 pts treated with 
ceritinib. BR: 2pts PR 
(NR previous EGFR-TKI 
treatment)
NR
Inamura 
et al [41]
1 pts. F, 55 Y, NS, 
Asiatic
-EGFR exon
19 deletion
-EML4-ALK variant 1
-second line 
gefitinib. BR:PR 
(PFS 31 mts)
-21 th line 
alectinib + 
gefitinib. BR:SD 
(PFS 5 mts)
-22 th line third 
generation of 
EGFR-TKIs. 
BR:PR
-19 th line crizotinib. 
BR:SD
-20 th line alectinib. 
BR:PD
-21 th line alectinib + 
gefitinib. BR:SD
-over 20 lines of 
treatment. Cytotoxic 
chemotherapy was 
generally less effective
Caliez et al 
[42]
2 pts. 2 F, 64 and 
45 Y, 1 NS,1 LS, 
Caucasian
-EGFR mutation NR
-EML4-ALK variant NR
-Pts N1 second 
line erlotinib. 
BR:SD ( PFS 
14 mts)
-Pts N 2 second 
line afatinib. 
BR:SD (PFS 
8 mts)
-Pts N1 forth line 
crizotinib. BR:PR (PFS 
24 mts)
-Pts N2 third line 
crizotinib. BR:PD (PFS 
1 mts)
-Pts N1 first 
line cisplatin + 
gemcitabine, followed 
by 17 months of 
gemcitabine. BR:PR
-Pts N1 third line 
paclitaxel (PFS:6 mts)
-Pts N2 first line 
cisplatin + gemcitabine 
(PFS 8 mts)
Galetta 
et al [43]
1 pts. F, 76 Y, NS, 
Caucasian
-EGFR exon 19 deletion
-EML4-ALK variant NR
-second line 
gefitinib. BR:PR 
(PFS 6 mts)
-third line crizotinib. 
BR:PD
-first line cisplatin + 
pemetrexed. BR:PR
Fan T [44] 
et al
1 pts. F, 63 Y, NS, 
Asiatic
-EGFR exon19 deletion
-EML4-ALK variant NR
NT NT -first line carboplatin + 
pemetrexed. BR:NR
Zhou J et al 
[45]
1 pts. F, 47 Y, NS, 
Asiatic
-EGFR exon 19 deletion
-EML4-ALK variant NR
-second line 
gefitinib. BR:PD 
(PFS 2 mts)
NT -first line cisplatin + 
gemcitabine. BR:NR
Rossing 
HH et al 
[46]
1 pts. M, 61 Y, NS, 
Caucasian
-EML4-ALK variant NR
-acquired EGFR exon 21 
(L862R)mutation
-acquired KRAS codon 
13 (c.38G > A, p.G13D) 
mutation
NT -second line crizotinib. 
BR:PR (PFS 8 mts)
-first line carboplatin-
vinorelbine 
-bevacizumab. BR :PR
-third-line pemetrexed. 
BR:PD
(Continued )
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with 20 cases of response (51.3%). Twenty three patients 
were treated with both EGFR and ALK-TKIs (27 lines 
of EGFR-TKIs and 27 lines of ALK-TKIs administered). 
Twenty two patients (95.6%) received EGFR-TKIs before 
ALK-TKIs. In this subgroup the percentage of disease 
control and the percentage of objective response with 
EGFR-TKIs were 61.5% (16 of 26 evaluable treatment 
lines showed CR or PR or SD as best response) and 
23.1% (6 of 26 evaluable treatment lines showed CR or 
PR as best response) respectively whilst with ALK-TKIs 
the percentage of disease control and the percentage 
of objective response were 73.1% (19 of 26 evaluable 
treatment lines) and 42.3% (11 of 26 evaluable treatment 
lines) respectively. (Table 2).
DISCUSSION
In recent years the study of molecular characteristics 
of lung cancer has underlined the pathogenic and 
therapeutic importance of specific genes involved in 
tumor growth. The most significant discovery was 
undoubtedly the role as therapeutic target of EGFR and 
ALK in the non squamous histology, but many other 
genes involved in the cell proliferation process have 
Author Pts characteristics Biomolecular characterization
EGFR-TKI 
treatment ALK-TKI treatment Other treatments
Lee T et al 
[48]
6 pts. 1 M 5 F, 
median age 62 Y, 5 
NS 1 LS, Asiatic
-EGFR: 2 pts exon 18 
G719X, 1 pts exon 21 
L858R, 1 pts both exon 18 
G719X and exon 21 L858R, 
1 pts exon 19 deletion, 1 pts 
exon 20 R803W
-EML4-ALK variant NR
-2 pts treated 
with gefitinib. 
BR:1 pts PR 1 
pts SD
-1 pts treated 
with erlotinib 
BR:PD
3 pts treated with 
crizotinib.BR: 1 pts 
PR, 1pts SD, 1 pts NR. 
(Only 1 pts previously 
treated with gefitinib 
SD→PR)
NR
Ulivi et al 
[49]
6 pts.1 M 5 F, 
median age 60 
Y,3 NS 2 FS 1CS, 
Caucasian
-EGFR: 5 pts exon 19 
deletion, 1 pts exon 21 
(L858R) mutation.
-EML4-ALK variant NR
-5 pts first line 
gefitinib.BR: 
1 pts CR,2 pts 
PR,2 pts PD
-1 pts first line 
erlotinib. BR:PR
-1 pts second line 
crizotinib. BR:NR. (NR 
previous EGFR TKI 
treatment)
NR
Sahnane N 
et al [50]
3 pts. 1 M 2 F, 51-
67-74 Y, 2 NS 1 NR, 
Caucasian
-EGFR: 1 pts exon 19 
deletion, 1 pts exon 21 
(L858R) mutation, 1 pts exon 
18 G719A mutation
-EML4-ALK variant NR
-2 pts first line 
erlotinib. BR: 1 
pts PD,1 pts SD 
(PFS 8 mts)
-1 pts second 
line crizotinib. 
BR:SD(previously 
treated with erlotinib 
.BR:SD)
-1 pts third line 
crizotinib. BR: PR 
(previously treated with 
erlotinib .BR:PD)
-1 pts second line 
carboplatin + 
gemcitabine. BR:PD ( 
3 cycles)
Guibert N 
et al [52]
10 pts. Other 
clinical data NR
-EGFR mutation NR
-EML4-ALK variant NR
NR -1 pts treated with 
crizotinib. BR:SD
NR
Our cases 2 pts. 1 M 1 F, 52-43 
Y, 2 NS, Caucasian
-EGFR: 2 pts exon 19 
deletion
-EML4-ALK variant NR
-Pts N1first line 
geftinib for 2 
months (stopped 
for toxicity). 
BR:NE
-Pts N1 third 
line erlotinib. 
BR:PD
-Pts N2 first line 
geftinib. BR:PD
-Pts N2 third 
line erlotinib. 
BR:SD
-Pts N1 fifth line 
crizotinib. BR:PR (PFS 
24 mts)
-Pts N1 7th line ceritinib. 
BR:PD
-Pts N2 second line 
crizotinib (stopped for 
toxicity). BR:NE
-Pts N2 forth line 
ceritinib. BR: PR
-Pts N1second 
line cisplatin + 
gemcitabine. BR:PD
-Pts N1 forth line 
pemetrexed .BR:PR
-Pts N1 sixth line 
vinorelbine. BR:PD
EML4-ALK = echinoderm microtubule associated protein like 4 -anaplastic lymphoma kinase, EGFR = epidermal growth factor receptor, 
pts = patients, TKI = tyrosine-kinase inhibitor, F = female, Y = years, mts = months, NS = never smokers, NR = not reported, BR = best 
response, N = number, SD = stable disease, PFS = progression free survival, PR = partial response, PD = progressive disease, M = male, 
CS = current smokers, NT = not treated, HS = high smokers, CR = complete response, LH = light smokers, FS = former smokers, NE = 
not evaluable.
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been investigated. The oncogene KRAS is mutated in 
20-30% of lung adenocarcinomas, particularly in heavy 
smokers and in the Caucasian population. However 
its role is still controversial both as a prognostic and 
predictive factor. Other molecular alterations have already 
demonstrated a promising therapeutic impact, especially 
in lung adenocarcinomas. They are represented by the 
ROS1 and RET gene rearrangements (about 1-2% of 
lung adenocarcinomas) and by the activating mutations 
of BRAF (V600E and others) and HER2. Also the 
FGFR1 and PDGFR amplification and the mutations of 
PI3KCA, PTEN and DDR2 could have future therapeutic 
implications, especially in squamous cell lung cancer. 
[4, 12]. Anyhow at present only the discovery of EGFR 
and ALK molecular alterations has radically changed 
the clinical history of two specific subgroup of patients 
(EGFR mutated and EML4-ALK rearranged patients). 
[13, 14] In the first years after its discovery the presence 
of ALK rearrangement has been described as mutually 
exclusive with the presence of EGFR mutations [15–20]. 
Some authors reported that ALK rearrangements were 
more common in patients with poorly differentiated 
adenocarcinoma whilst EGFR mutations were typical 
of well-differentiated cancers [15]. In the same way 
the coexistence of KRAS mutations with the other 
two alterations was described as virtually impossible. 
Thus the initial suggested algorithms for bio-molecular 
characterization of non squamous NSCLC proposed 
testing the histological samples for KRAS mutations 
followed by EGFR test only if KRAS was wild type. ALK 
testing was to be performed only if no alterations were 
found in previous tests [16–20].
However a higher number of subsequent 
observations demonstrated that the concomitant presence 
of EML4-ALK rearrangements and EGFR mutations is rare 
but not irrelevant [9–11, 21–45] (Table 1), and also the 
coexistence with KRAS and other mutations is possible 
[46–52]. So at present this diagnostic algorithm cannot be 
considered the gold standard.
In regards to patients with both EML4-ALK 
rearrangements and EGFR mutations, literature data 
are conflicting. Yang et al [34] and Ulivi et al [49] 
reported a percentage of concurrent alterations of 1.3% 
and 1.6% respectively, whilst Lee et al described only 6 
cases of concomitant alterations on 6637 NSCLC cases 
[48]. In some cases the presence of EGFR mutations is 
described as a resistance mechanism occurring in patients 
with EML4-ALK translocations treated with ALK-TKIs 
[46, 51]. At the same time the development of EML4-
ALK rearrangements could be an acquired resistance 
mechanism after EGFR-TKIs treatment, although the 
second event is considered more rare [23, 41]. Other 
authors reported that both genetic alterations could be 
present from the beginning of tumor proliferation [23, 
34, 35, 39]. The different cellular clones represent the 
expression of the heterogeneity of tumors [39]. Moreover 
these two bio-molecular alterations may coexist in the 
same tumor cell [35]. In our opinion all mechanisms are 
possible and can probably occur in the same patient during 
the course of the disease.
Another hot topic is the variable response reported 
to both ALK-TKIs and EGFR-TKIs in the different 
published cases. Some authors hypothesized that the 
coexistence of two alterations could be predictive 
of poor response in patients treated with TKIs [24, 
43, 46]. These data however, were not confirmed by 
other authors, that reported a good sensitivity to these 
treatments [22, 25, 33]. Furthermore some papers 
showed a better outcome only in patients treated with 
first line ALK-TKIs [34, 40, 48] whilst an unsatisfactory 
response was reported with first line EGFR-TKIs [30, 
31, 35]. Again these results are not confirmed by other 
experiences [22, 25, 33, 52].
Despite the increasing number of reported cases of 
coexistent alterations, these are still not frequent enough 
to allow the authors to define specific guidelines and at 
present it is not possible to establish the best sequence of 
treatments. The two cases reported here are an example 
Table 2: Qualitative synthesis of reported best responses
Treatment N Pts N Lines# N CR+PR N SD N PD CR+PR (%) DC (%)
EGFR-TKIs 51 53 23 14 16 43,4 69.8
ALK-TKIs 37 39 20 11 8 51.3 79.5
EGFR + 
ALK-TKIs 23*
-26 EGFR-
TKI lines
-26 ALK-TKI 
lines
-6 with 
EGFR-TKIs
 -11 with 
ALK-TKIs
-10 with 
EGFR-TKIs
 -8 with ALK-
TKIs
-10 with 
EGFR-TKIs
 -7 with ALK-
TKIs
-23.1 with 
EGFR-TKIs
 -42.3 with 
ALK-TKIs
-61.5 with 
EGFR-TKIs
 -73.1 with 
ALK-TKIs
N = number, Pts = patients, CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, 
NE = not evaluable, DC = disease control, EGFR-TKI = epidermal growth factor receptor tyrosine-kinase inhibitor, ALK-
TKI = anaplastic lymphoma kinase receptor tyrosine-kinase inhibitor.
* Twenty two patients (95.6%) received first EGFR-TKI before the first ALK-TKI.
# Evaluable for response.
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of this ambiguous context. Both patients had concomitant 
EGFR mutation and ALK rearrangement ab initio. They 
were both treated upfront with an EGFR-TKI (gefitinib) 
followed by another drug of the same family (erlotinib). 
The first patient did not respond to either treatments, while 
in the second case we obtained a PR with gefitinib and 
a long SD with erlotinib. Both patients were also treated 
with two ALK-TKIs (crizotinib and ceritinib). The first 
patient achieved a long SD after crizotinib but did not 
respond to ceritinib. In the second case the response to 
crizotinib was not evaluable because it was withdrawn 
due to an important toxicity, but the patient reported an 
outstanding response with ceritinib. Thus also in our 
experience, data are very dishomogeneous and do not 
allow us to draw any conclusions. Nevertheless we can 
give some suggestions on the basis of the qualitative data 
synthesis.
Considering literature data and the great efficacy 
of both ALK and EGFR-TKIs, it is strongly advised 
that EGFR and ALK tests are performed ab initio in all 
advanced non squamous NSCLC.
Figure 1: Flow diagram of the study selection process.
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Although there is no literature consensus, and 
our analysis is only a descriptive non statistical data 
synthesis, ALK-TKIs seem to be slightly more effective 
than EGFR-TKIs in patients with both alterations (Table 
2). Disease control or disease response are reported as 
best response in 69.8% and 43.4 % versus 79.5% and 
51.3% of reviewed cases treated with EGFR and ALK-
TKIs respectively. Twenty three patients received both 
EGFR and ALK-TKIs. In the great majority of cases (22 
patients) EGFR-TKIs were administered before ALK-
TKIs. Despite this fact, in this subgroup of patients, 
disease control was achieved in 61.5% versus 73.1% and 
disease response was seen in 23.1% versus 42.3% of 
cases treated with EGFR versus ALK-TKIs respectively. 
Furthermore also the role of chemotherapy in these 
patients is still debated [52]. Obviously, the very limited 
number of evaluable patients does not allow us to draw 
definitive conclusions but in our opinion, ALK-TKIs 
treatment could be the preferred first line approach, 
if there aren’t any other data that could guide the 
therapeutic choice.
EGFR mutations, ALK translocations and many 
other bio-molecular alterations [53] may appear 
in the course of the disease as acquired resistance 
mechanisms after EGFR and ALK-TKIs treatment. 
Thus, if technically feasible, it is crucial to re-biopsy 
all patients with PD in order to detect all possible new 
alterations and design therapy on the basis of the new 
bio-molecular status.
Patients with EGFR mutations and EML4-ALK 
translocations have a higher incidence of brain metastases 
[54]. These are also present in our two cases. To date 
WBRT and Stereotactic Radiosurgery (SRS) represent 
the most used treatments in patients with intracranial 
involvement [55]. Nevertheless EGFR and ALK-TKIs, 
especially the new-generation drugs, have shown relevant 
intracranial activity [56–58]. Therefore the TKIs role and 
their correct place within the therapeutic strategy are still 
debated, especially for patients with brain metastasis and 
both alterations.
Since the two alterations may coexist ab initio, 
another very interesting future perspective could be to test 
the safety and the potential efficacy of a double inhibition 
of both ALK and EGFR. Designing clinical trials specific 
for these patients could be very fascinating and could 
answer many open questions. However, due the rarity 
of this condition, it would be difficult to recruit the right 
number of patients.
In conclusion, an accurate bio-molecular 
characterization is crucial to drive the therapeutic strategy 
of NSCLC with multiple driver alterations. Perhaps the 
allelic alteration’s fraction in NGS or the liquid biopsies 
could be useful in defining the best therapeutic choice 
[52]. All available clinical data should be shared and 
analyzed in order to increase our experiences and correctly 
manage these patients.
MATERIALS AND METHODS
We performed a literature review on reported cases 
and case series of concomitant EML4-ALK rearrangement 
and EGFR mutation in patients with NSCLC. We collected 
all available clinical data and investigated treatment strategies 
used in the management of this rare group of tumors. We 
searched the digital databases using these keywords: “Non-
Small Cell Lung Cancer”, “EML4-ALK rearrangements”, 
“EGFR mutations”, variously associated with “concomitant”, 
“coexistence”, “coexistent”, “concurrent”, “both”, “same 
tumor”, “same cancer”, “same neoplasm”. We did not 
restrict the search to English language but we included in the 
analysis only the publications for which an English abstract 
was available. We focused our attention mainly on the drugs 
used and treatment efficacy. We read the full text of selected 
papers (abstracts were analyzed when the English version 
of the article was not present). The reference list of selected 
papers was also used in the selection process.
We examined 923 papers, 865 works were excluded 
based on title and abstract content while, the remaining 58 
papers were included in our review. Thirty three studies, 
were selected for qualitative synthesis (Table 1), (Figure 1).
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